What is PT-141, and what is actually approved?
PT-141 is the development name for bremelanotide, a synthetic peptide that activates melanocortin receptors. The US-approved product is Vyleesi, a prescription injection under the skin. Its indication is specific: acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women.[1]
Acquired means the problem developed after a period without low desire. Generalized means it occurs across situations, types of stimulation or partners. The low desire must cause marked distress or interpersonal difficulty and must not be explained by a medical or psychiatric condition, a relationship problem, or a medication or drug effect. Low desire on its own does not establish this diagnosis.[1]
The US label does not indicate Vyleesi for men, postmenopausal women or improving sexual performance. Approval of that particular subcutaneous product also does not establish that a nasal spray, a compounded vial or a product sold for research is equivalent.[1]
What does the mechanism tell us?
Bremelanotide activates several melanocortin receptor subtypes. The label identifies MC1 and MC4 as the most relevant at therapeutic exposure, with MC4 receptors present in the central nervous system. It also states that the mechanism by which Vyleesi improves HSDD is unknown. Receptor activity gives researchers a rationale; it does not fully explain a person's response.[1]
Early work included erectile responses in rats, nonhuman primates and men. Those observations helped establish a research direction. They are different from demonstrating a reliable treatment for low desire in every population.[3]
How much benefit did the approved trials show?
The two RECONNECT trials randomized 1,267 premenopausal women with HSDD to bremelanotide or placebo for 24 weeks. Of those, 1,247 entered the safety population and 1,202 the primary efficacy population. Participants used the study injection as needed.[2]
Both trials met their two main endpoints: self-reported sexual desire improved, and distress about low desire decreased. Across the studies, the placebo-adjusted difference was 0.35 points on the desire scale, which runs from 1.2 to 6, and a 0.33-point reduction on the distress item, which runs from 0 to 4. The average differences were modest, although some participants reported a meaningful benefit.[1][2]
The key secondary endpoint did not improve significantly: the number of satisfying sexual events. A later exploratory analysis looked at the proportion of encounters considered satisfying, but that does not turn the unsuccessful prespecified count outcome into a positive result.[2]
The studies also had substantial dropout. In the label's efficacy population, about 40% of bremelanotide recipients stopped before completing the double-blind period, compared with 13% and 25% in the two placebo groups. Most participants were White and in stable relationships. Those features matter when applying the findings to a broader population.[1]
What did participants experience?
The trial reports give us a better basis than anonymous testimonials. Nausea occurred in 40% of bremelanotide recipients versus 1.3% with placebo, and about 8% stopped because of nausea. Flushing, injection-site reactions, headache and vomiting were also common. Most reported events were mild or moderate, but serious events occurred, including a hospitalization for vomiting and headache considered related to treatment.[1][2]
The current label also reports that pretreatment with ondansetron did not reduce Vyleesi-associated nausea in a placebo-controlled study. That study did not establish ondansetron as a way to prevent the nausea.[1]
The safety restrictions are specific
Vyleesi can temporarily raise blood pressure and lower heart rate after a dose. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. The label also advises against use in people at high cardiovascular risk. These are more specific restrictions than a general suggestion to monitor blood pressure.[1]
Focal darkening of the skin, gums or breasts occurred in about 1% of participants using up to eight doses per month. Risk was higher with darker skin and frequent dosing, and resolution was not confirmed in every affected person. The label also warns that slower stomach emptying can change the absorption of oral medicines, including substantially reducing oral naltrexone exposure.[1]
Pregnancy, medicines and kidney or liver problems belong in the clinical assessment. The label advises effective contraception and stopping if pregnancy is suspected. It also directs stopping after eight weeks if there is no improvement, rather than continuing indefinitely without benefit.[1]
What about use in men?
A 2004 placebo-controlled report found increased erectile responses after intranasal PT-141 in healthy men and men whose erectile dysfunction responded to sildenafil. Nausea and flushing were common reported adverse effects. This was early research using a nasal formulation and an erectile-response measurement, not evidence that the approved injection treats male low desire.[4]
A larger, often-cited intranasal study in men who had not responded to sildenafil received an expression of concern in 2023. Its efficacy claims should not be treated as secure evidence. That notice concerns a different study from the RECONNECT trials used for Vyleesi's approval.[5]
Does the obesity research change its approved use?
No. A sponsor conference poster described 96 people randomized after an initial four weeks of tirzepatide. It reported weight-loss signals with bremelanotide combinations during a further four weeks, but this was a short study with small, unequal groups. Skin darkening was reported in 47% of the combination group and 50% of the bremelanotide-only group during that period. The daily bremelanotide schedule also differed from Vyleesi's approved as-needed use.[8]
As checked on November 9, 2026, the registry still listed an estimated enrollment of 108 and had no posted results. A poster is a report of findings, but it does not provide the same detail as a complete peer-reviewed trial report. This research does not establish an approved obesity indication or justify transferring the HSDD dosing instructions to weight management.[7][8]
Putting the evidence in place
Approved population
Premenopausal women with acquired, generalized HSDD meeting the label's diagnostic criteria.
Demonstrated benefit
Modest average improvements in desire and related distress in two placebo-controlled trials.
Limits of benefit
The satisfying-event count did not improve significantly. Not everyone benefited or completed treatment.
Other applications
Male, nasal and obesity uses require their own evidence and are outside this US indication.
Useful questions for a clinical conversation
The diagnosis
- What is contributing to my change in desire?
- Do I meet the specific HSDD criteria?
- Could another condition, medication or relationship issue explain it?
The product and risks
- Is the proposed product the approved subcutaneous formulation?
- How do my cardiovascular history and medicines affect suitability?
- What should happen if nausea, pigmentation or other effects occur?
The result
- What improvement would matter to me?
- How will we assess benefit rather than simply count doses?
- When would we stop or consider a different approach?
What to take away
Bremelanotide has controlled trial evidence and a specific US-approved use. The useful decision is whether its modest average benefit, individual response and known risks fit a properly assessed diagnosis. The name PT-141 alone does not tell you that the product or proposed use matches that evidence.
Questions people ask
Who is Vyleesi approved for in the US?
Vyleesi is approved for acquired, generalized HSDD in premenopausal women when low desire causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, a relationship problem, or a medication or drug effect. It is not indicated for men, postmenopausal women or sexual-performance enhancement.
Does PT-141 work for men?
Early intranasal studies reported increased erectile responses in men, but these findings do not establish that the approved subcutaneous injection treats male low desire. A larger male study has an expression of concern. The US Vyleesi indication does not include men.
What are the main risks?
Nausea is common and led about 8% of treated trial participants to stop. Other risks include temporary blood-pressure increases, lower heart rate and skin darkening that may persist. Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. It can also affect absorption of oral medicines.
Is Vyleesi a daily treatment?
No. The approved product is an as-needed subcutaneous injection. Its label limits frequency and directs stopping after eight weeks if symptoms have not improved. The daily regimen studied in an obesity trial is a different investigational use, not the approved HSDD schedule.
The evidence
Sources used for this article. The labels distinguish original trials, observational findings, research context and regulatory information.
Sources checked November 9, 2026. The current US label, original RECONNECT report, older study abstracts, publication notices, registry records and obesity poster were checked. Approval statements are specific to the US product and indication.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. PT-141 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.